Mwandishi:
Mhariri:
ULY CLINIC
Dkt. Helen L, MD
16 Oktoba 2021 11:27:48
Aspirin kwa mjamzito
Matumizi ya aspirini wakati wa ujauzito haswa matumizi ya muda mrefu kwa dozi ndogo au matumizi ya mara moja moja katika dozi kubwa yanapaswa kuachwa. Dawa hii inaweza kudhuru hali ya ugandaji damu kwa mama na mtoto hivyo kuongeza hatari ya mtoto kufa, kutokuwa vema tumboni na mwama na ulemavu.
Dozi kidogo ya miligramu 80 kwa siku imeonekana kuwa na faida kwa ujauzito wa mama mwenye lupus iliyosamba pamoja na antibody za antifosfolipidi kwenye damu.
Kwenye ujauzito wenye hatari ya kupata shinikizo la damu la ujauzito pamoja na shinikizo la damu linaloelekea kifafa cha mimba, matumizi ya dozi ndogo (miligramu 40-150 kwa siku) yameonekana kuwa na faida hata hivyo tafiti zaidi zinahitajika kuchunguza hatari faida ya matumizi dhidi ya madhara yanayoweza kujitokeza.
Matumizi ya aspirini karibia na mwishoni mwa ujauzito huweza kufanya mama achelewe kujifungua kutokana na leba kudumu kwa muda mrefu.
Aspirini imekuwa ikitumika pia kama kituliza tumbo lenye mijongeo, matumizi haya yanaweza kusababisha kutokwa na damu nyingi kwa kichanga.
Kuwahi kufunga kwa mshipa wa damu wa ductus arteriosus hutokea kama mama atatumia dozi nzima kwa pamoja ya aspirin mwishoni mwa ujauzito. Kufunga kwa mshipa huu hupelekea shinikizo endelevu la damu kenye palimonari (PPHN) kwa mtoto.
Kama kuna mahitaji ya dawa ya kupunguza maumivu au kushusha homa, inashauriwa kutumia paracetamol badala ya aspirini.
Matumizi wakati wa ujauzito
Dozi ndogo
Inapatana na ujauzito
Dozi ndogo inapatana na ujauzito ina maana gani?
Uzoefu wa matumizi kwa binadamu kuhusu dawa hii au dawa zingine zilizo kundi moja au zenye kufanya kazi kwa utaratibu unaofanana, zinatosha kuonyesha kuwa, madhara kwa kichanga tumboni ni madogo sana au hakuna kabisa. Tafiti za uzazi kwa wanyama hazina uhalisia kwa binadamu.
Dozi kubwa
Taarifa za binadamu zinaonyesha hatari kwenye kipindi cha kwanza na tatu cha ujauzito
Taarifa za binadamu zinaonyesha hatari kwenye kipindi cha kwanza na tatu cha ujauzito ina maana gani?
Ushahidi wa matumizi ya dawa hii au zingine zinazofanana na dawa hii kwenye ujauzito zinaonekana kuwa ni sumu kwa ukuaji wa tumboni kwa na kusababisha madhaifu ya uumbaji, ukuaji, viungo vya mwili, ufanyaji kazi wa viungo, tabia au kusababisha kifo cha kichanga au kijusi tumboni katika kipindi cha kwanza na tatu tu cha ujauzito lakini si katika kipindi cha pili. Taarifa za madhara ya dawa hii kwa binadamu zinamashiko zaidi kuliko taarifa za tafiti kwa wanyama.
Matumizi wakati wa kuonyesha
Hakuna (chache) taarifa kwa binadamu- inawezekano mkubwa wa kuwa sumu kwenye ukuaji wa kichanga
Hakuna (chache) taarifa kwa binadamu- inawezekano mkubwa wa kuwa sumu kwenye ukuaji wa kichanga ina maanisha nini?
Inaweza kuwa taarifa juu ya matumizi kwa kichanga anayenyonya maziwa ya mama anayetumia dawa hii hazipo au zipo chache. Sifa za ufanyaji kazi wa dawa zinaonyesha kuwa aspirin inaweza kuwa sumu kwa kichanga anayenyonyeshwa maziwa ya mama aliyetumia dawa. Hairuhusiwi kumnyonyesha mtoto unapotumia aspirini
ONYO: Usitumie dawa yoyote bila ushauri wa daktari. Dawa zinaweza kuleta madhara mwilini na pia matumizi ya baadhi ya dawa pasipo ushauri na vipimo husababisha vimelea kuwa sugu dhidi ya dawa hiyo.
ULY clinic inakushauri kuwasiliana na daktari wako unapotaka kuchukua maamuzi yoyote yanayohusu afya yako.
Wasiliana na daktari/Mfamasia wa ULY clinic kwa ushauri na Tiba au kuandikiwa dawa kwa kupiga simu au Kubonyeza Pata tiba chini ya tovuti hii.
Imeboreshwa,
1 Julai 2023 17:21:49
Rejea za mada hii;
1. Corby DG. Aspirin in pregnancy: maternal and fetal effects. Pediatrics 1978;62(Suppl):930–7.
2. Palmisano PA, Cassady G. Salicylate exposure in the perinate. JAMA 1969;209:556–8.
3. Forfar JO, Nelson MM. Epidemiology of drugs taken by pregnant women: drugs that may affect the fetus adversely. Clin Pharmacol Ther 1973;14:632–42.
4. Finnigan D, Burry AF, Smith IDB. Analgesic consumption in an antenatal clinic survey. Med J Aust 1974;1:761–2.
5. Collins E, Turner G. Maternal effects of regular salicylate ingestion in pregnancy. Lancet 1975;2:335–7.
6. Slone D, Heinonen OP, Kaufman DW, Siskind V, Monson RR, Shapiro S. Aspirin and
1. congenital malformations. Lancet 1976;1:1373–5.
7. Hill RM, Craig JP, Chaney MD, Tennyson LM, McCulley LB. Utilization of over-the-counter drugs during pregnancy. Clin Obstet Gynecol 1977;20:381–94.
8. Harrison K, Thomas I, Smith I. Analgesic use during pregnancy. Med J Aust 1978;2:161.
9. Bodendorfer TW, Briggs GG, Gunning JE. Obtaining drug exposure histories during pregnancy. Am J Obstet Gynecol 1979;135:490–4.
10. Jackson AV. Toxic effects of salicylate on the foetus and mother. J Pathol Bacteriol 1948;60:587–93.
11. Lewis RN, Schulman JD. Influence of acetylsalicylic acid, an inhibitor of prostaglandin synthesis, on the duration of human gestation and labour. Lancet 1973;2:1159–61.
12. Rudolph AM. Effects of aspirin and acetaminophen in pregnancy and in the newborn. Arch Intern Med 1981;141:358–63.
13. Stuart MJ, Gross SJ, Elrad H, Graeber JE. Effects of acetylsalicylic-acid ingestion on maternal and neonatal hemostasis. N Engl J Med 1982;307:909–12.
14. Stuart MJ. Aspirin and maternal or neonatal hemostasis. N Engl J Med 1983;308:281.
15. Niebyl JR, Blake DA, Burnett LS, King TM. The influence of aspirin on the course of induced midtrimester abortion. Am J Obstet Gynecol 1976;124:607–10.
16. Castellanos JM, Aranda M, Cararach J, Cararach V. Effect of aspirin on oestriol excretion in pregnancy. Lancet 1975;1:859.
17. Babenerd VJ, Kyriakidis K. Acetylsalicylic acid in the prevention of premature delivery. Fortschr Med 1979;97:463–6.
18. Wolff F, Bolte A, Berg R. Does an additional administration of acetylsalicylic acid reduce the requirement of betamimetics in tocolytic treatment? Geburtshilfe Frauenheilkd 1981;41:293–6.
19. Wolff F, Berg R, Bolte A. Clinical study of the labour inhibiting effects and side effects of acetylsalicylic acid (ASA). Geburtshilfe Frauenheilkd 1981;41:96–100.
20. Buhler M, Papiernik E. Successive pregnancies in women fitted with intrauterine devices who take antiinflammatory drugs. Lancet 1983;1:483.
21. Goodlin RC. Correction of pregnancy-related thrombocytopenia with aspirin without improvement in fetal outcome. Am J Obstet Gynecol 1983;146:862–4.
22. Gant NF. Lupus erythematosus, the lupus anticoagulant, and the anticardiolipid antibody.
23. Supplement No. 6, May/June 1986, to Pritchard JA, MacDonald PC, Gant NF. Williams Obstetrics. 17th ed. Norwalk, CT: Appleton-Century-Crofts, 1985.
24. Branch DW, Scott JR, Kochenour NK, Hershgold E. Obstetric complications associated with the lupus anticoagulant. N Engl J Med 1985;313:1322–6.
25. Elder MG, DeSwiet M, Robertson A, Elder MA, Flloyd E, Hawkins DF. Low-dose aspirin in pregnancy. Lancet 1988;1:410.
26. Lockshin MD, Druzin ML, Qamar T. Prednisone does not prevent recurrent fetal death in women with antiphospholipid antibody. Am J Obstet Gynecol 1989;160:439–43.
27. Beaufils M, Uzan S, Donsimoni R, Colau JC. Prevention of preeclampsia by early antiplatelet therapy. Lancet 1985;1:840–2.
28. Beaufils M, Uzan S, Donsimoni R, Colau JC. Prospective controlled study of early antiplatelet therapy in prevention of preeclampsia. Adv Nephrol 1986;15:87–94.
29. Ylikorkala O, Makila U-M, Kaapa P, Viinikka L. Maternal ingestion of acetylsalicylic acid inhibits fetal and neonatal prostacyclin and thromboxane in humans. Am J Obstet Gynecol 1986;155:345–9.
30. Spitz B, Magness RR, Cox SM, Brown CEL, Rosenfeld CR, Gant NF. Low-dose aspirin. I. Effect on angiotensin II pressor responses and blood prostaglandin concentrations in pregnant women sensitive to angiotensin II. Am J Obstet Gynecol 1988;159:1035–43.
31. Wallenburg HCS, Rotmans N. Prevention of recurrent idiopathic fetal growth retardation by low-dose aspirin and dipyridamole. Am J Obstet Gynecol 1987;157:1230–5.
32. Wallenburg HCS, Rotmans N. Prophylactic low-dose aspirin and dipyridamole in pregnancy. Lancet 1988;1:939.
33. Uzan S, Beaufils M, Bazin B, Danays T. Idiopathic recurrent fetal growth retardation and aspirin-dipyridamole therapy. Am J Obstet Gynecol 1989;160:763.
33. Wallenburg HCS, Rotmans N. Idiopathic recurrent fetal growth retardation and aspirindipyridamole therapy. Reply. Am J Obstet Gynecol 1989;160:763–4.
34. Sibai BM, Mirro R, Chesney CM, Leffler C. Low-dose aspirin in pre
35. Klebanoff MA, Berendes HW. Aspirin exposure during the first 20 weeks of gestation and IQ at four years of age. Teratology 1988;37:249–55.
36. Matt DW, Borzelleca JF. Toxic effects on the female reproductive system during pregnancy, parturition, and lactation. In: Witorsch RJ, ed. Reproductive Toxicology. 2nd ed. New York, NY: Raven Press, 1995:175–93.
37. Daewood MY. Nonsteroidal antiinflammatory drugs and reproduction. Am J Obstet Gynecol 1993;169:1255–65.
38. Hernandez RK, Werler MM, Romitti P, Sun L, Anderka M; National Birth Defects Prevention Study. Nonsteroidal antiinflammatory drug use among women and the risk of birth defects. Am J Obstet Gynecol 2012;206:228.e1–8.
39. Kwit NT, Hatcher RA. Excretion of drugs in milk. Am J Dis Child 1935;49:900–4.
40. Erickson SH, Oppenheim GL. Aspirin in breast milk. J Fam Pract 1979;8:189–90.
41. Weibert RT, Bailey DN. Salicylate Excretion in Human Breast Milk (Abstract No. 7). Presented at the 1979 Seminar of the California Society of Hospital Pharmacists, Los Angeles, October 13, 1979.
42. Findlay JWA, DeAngelis RL, Kearney MF, Welch RM, Findley JM. Analgesic drugs in breast milk and plasma. Clin Pharmacol Ther 1981;29:625–33.
43. Anderson PO. Drugs and breast feeding—a review. Drug Intell Clin Pharm 1977;11:208–23.
44. Clark JH, Wilson WG. A 16-day-old breast-fed infant with metabolic acidosis caused by salicylate. Clin Pediatr (Phila) 1981;20:53–4.
45. Committee on Drugs, American Academy of Pediatrics. The transfer of drugs and other chemicals into human milk. Pediatrics 2001;108:776–89.